palbociclib based treatment for COVID-19: living meta-analysis of clinical studies

display ongoing

results: demonstrated suggested inconclusive safety concern ongoing study

	breast cancer - adjuvant	breast cancer - HR positive

	breast cancer - adjuvant	la/mBC - HR positive	la/mBC - HR-positive - 1st line (L1)	la/mBC - HR-positive - 2nd line (L2)
palbociclib based treatment
palbociclib	PALLAS
palbociclib plus endocrine therapy	PENELOPE-B	KCSG-BR15-10	PENELOPE-B
palbociclib plus fulvestrant				PALOMA-3 FLIPPER
palbociclib plus letrozole			PALOMA-1 PALOMA-2

Study type: